On the other hand, TIM-3, which has been shown to inhibit antitumor immunity by mediating CD8 T-cell exhaustion and pathways involved in metastasis, is an emerging immune checkpoint in several cancers including CRC (30–32). This evidence concerns the gene HAVCR2 and cancer.